Compare Ascendis Pharma A/S (ASND) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Levi Strauss & Co. — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Levi Strauss & Co. trades at $24.25 (market cap $9.36B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Levi Strauss & Co. pays a 2.63% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LEVI | |
|---|---|---|
Market Cap | $17.74B | $9.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $24.83 |
52-Week Low | $163.32 | $17.92 |
Enterprise Value | $18.11B | $10.67B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Levi Strauss (LEVI) trades at $24.31, up 2.02% today, showing strong fundamental performance with consistent earnings beats and robust profitability metrics. The company recently raised its dividend and full-year guidance following Q2 2026 results, demonstrating confidence in its digital strategy and direct-to-consumer growth. Technical indicators show mixed signals with bearish overall momentum but strong support at $23. Analyst consensus remains overwhelmingly bullish with an 83% buy rating and $28 price target, representing 15% upside potential.
LEVI presents a compelling investment case with strong fundamentals, consistent earnings outperformance, and positive business momentum. Key opportunities include the successful digital transformation, expanding direct-to-consumer sales, and dividend growth. Risks include tariff pressures, foreign exchange volatility, and competitive retail landscape. The stock offers attractive valuation with 15% upside to consensus target, supported by strong cash flow generation and improving balance sheet metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
